PetVivo (PETV) Q2 2026 earnings summary

Executive summary

• Achieved record quarterly revenue of $303,284, up 51% year-over-year, and first-half revenue of over $600,784, up 85% year-over-year, driven by new product launches and expansion into the companion animal market.

• Expanded adoption of flagship Spryng product and launched Precise PRP, with strong uptake in the canine market, initial equine sales, and exclusive licensing agreements with VetStem and Digital Landia.

• Entered new international markets with distributors in Mexico, the UK, and Europe, targeting high-growth animal health sectors and uplisted to OTCQX Best Market.

• Formed strategic partnerships, including with VetStem, Commonwealth Markets, Digital Landia (AI), PiezoBioMembrane, and others for product and technology expansion.

• Appointed Josh Ruben to the board, bringing significant healthcare, capital markets, and strategic expertise.

Financial highlights

• Quarterly revenues were $303,284, up from $200,720 year-over-year; six-month revenues were $600,784, up from $324,470; distributor sales rose 35% to $237,000, representing 75% of total revenue.

• Gross profit was $220,058 (72.6% margin), up 23% in dollars but down from 89.5% margin due to product mix shift; gross margin improved from 63.8% in the prior quarter.

• Operating expenses decreased 3% to $2,285,425, driven by cost reductions and restructuring.

• Operating loss was $2.1 million, net loss was $3,007,809 ($0.11/share), mainly from increased interest expense; adjusted net loss improved 5% to $2.1 million.

• Cash at quarter-end was $768,000, up from $220,000 at prior fiscal year-end, due to financing activities; total liabilities dropped 79% to $1.1 million, mainly from debt conversion and settlements.

Outlook and guidance

• Expects continued strong sales momentum, record growth, and improving bottom line for fiscal 2026, with Q3 and Q4 typically strongest due to industry events and increased product awareness.

• Management anticipates further revenue growth from new product launches and expanded distribution partnerships, but expects continued need for additional capital to support commercialization and operations.